|
|
Volumn 27, Issue 2, 2001, Pages 225-227
|
|
Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia
a
b
c
a
c
HOSPITAL CLÍNIC
(Spain)
|
|
Author keywords
ALL; Bcr abl rearrangement; Rituximab
|
|
Indexed keywords
ANTILEUKEMIC AGENT;
ASPARAGINASE;
BCR ABL PROTEIN;
CD19 ANTIGEN;
CD2 ANTIGEN;
CD20 ANTIGEN;
CD22 ANTIGEN;
CD34 ANTIGEN;
CD5 ANTIGEN;
CD61 ANTIGEN;
COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DAUNORUBICIN;
FIBRINOGEN RECEPTOR;
GRANULOCYTE COLONY STIMULATING FACTOR;
HLA ANTIGEN;
HLA DR ANTIGEN;
MERCAPTOPURINE;
METHOTREXATE;
MICROSOMAL AMINOPEPTIDASE;
MITOXANTRONE;
MONOCLONAL ANTIBODY;
RITUXIMAB;
VINCRISTINE;
VINDESINE;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADULT;
ALLOGENIC BONE MARROW TRANSPLANTATION;
ARTICLE;
BLAST CELL;
BONE MARROW CELL;
BONE MARROW PURGING;
CASE REPORT;
CELL STRUCTURE;
CLINICAL EXAMINATION;
CLINICAL FEATURE;
FLOW CYTOMETRY;
GENE REARRANGEMENT;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HLA MATCHING;
HUMAN;
HUMAN CELL;
IN VIVO STUDY;
LEUKEMIA REMISSION;
LIVING DONOR;
MALE;
MINIMAL RESIDUAL DISEASE;
MOLECULAR GENETICS;
PERIPHERAL BLOOD STEM CELL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
FUSION PROTEINS, BCR-ABL;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, ACUTE;
MALE;
NEOPLASM, RESIDUAL;
TRANSPLANTATION, AUTOLOGOUS;
|
|
EID: 0035137643
PISSN: 02683369
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bmt.1702706 Document Type: Article |
|
Times cited : (33)
|
|
References (11)
|
